Human papillomavirus recombinant vaccine 15 valent - Shanghai Bovax Biotechnology
Alternative Names: 15-valent HPV recombinant vaccine - Shanghai Bovax Biotechnology; 15-valent HPV vaccine - Shanghai Bovax Biotechnology; 15vHPV vaccineLatest Information Update: 07 Oct 2025
At a glance
- Originator Shanghai Bovax Biotechnology
- Class Papillomavirus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Human papillomavirus infections
Most Recent Events
- 15 Jan 2025 Phase-II clinical trials in Human papillomavirus infections (In children, In adolescents, In adults, Prevention) in China (IM) (NCT06756269)